Browse studies, page 1076
Page 1076 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 Cardiovascular Diabetology, 2018
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis Cardiovascular Diabetology, 2016
- Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis Medical Sciences, 2020
- Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis Journal of the American Heart Association, 2020
- Lower extremity arterial disease in patients with diabetes: a contemporary narrative review Cardiovascular Diabetology, 2018
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis Diabetes Obesity and Metabolism, 2019
- Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER Nature Medicine, 2022
- The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy Frontiers in cardiovascular medicine, 2023
- Physiological Conditions, Bioactive Ingredients, and Drugs Stimulating Non-Shivering Thermogenesis as a Promising Treatment Against Diabesity Pharmaceuticals (Basel, Switzerland), 2025
- Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease Frontiers in endocrinology, 2023
- Autologous Cell Therapy for Chronic Limb Threatening Ischemia: Towards Personalized Medicine Angiology, 2026
- Myocardial fibrosis and glycolysis: a bibliometric study and visualization analysis (2000-2024) Journal of translational medicine, 2026
- A Clinical Review of the Connections Between Diabetes Mellitus, Periodontal Disease, and Cardiovascular Pathologies Biomedicines, 2025
- The oxidative stress paradigm in arbovirus infections: mechanisms and therapeutic insights Redox report : communications in free radical research, 2026
- The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification Clinical and translational science, 2026
- Novel antidiabetic drugs and cardiovascular risk: Primum non nocere Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016
- Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? Heart failure reviews, 2022
- A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes Expert opinion on drug safety, 2016
- Leptin, cardiovascular diseases and type 2 diabetes mellitus Acta pharmacologica Sinica, 2018
- CaMKII and GLUT1 in heart failure and the role of gliflozins Biochimica et biophysica acta. Molecular basis of disease, 2020
- A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans Naunyn-Schmiedeberg's archives of pharmacology, 2015
- New hypoglycemic agents and the kidney: what do the major trials tell us? F1000Research, 2018
- Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease Advances in therapy, 2021
- Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus Revista da Associacao Medica Brasileira (1992), 2017
- New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors Orvosi hetilap, 2012
- SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus Current molecular pharmacology, 2021
- Empagliflozin for the treatment of Type 2 diabetes Expert review of clinical pharmacology, 2014
- The effect of SGLT2 inhibitors on cardiovascular events and renal function Expert review of clinical pharmacology, 2017
- The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus Annual review of medicine, 2015
- Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease Pharmacology & therapeutics, 2023
- A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes Expert opinion on drug safety, 2017
- Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management Current pharmaceutical design, 2017
- Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Journal of diabetes investigation, 2017
- Updates on cardiovascular outcome trials in diabetes Cardiovascular diabetology, 2017
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors European journal of heart failure, 2017
- New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold Journal of cardiovascular medicine (Hagerstown, Md.), 2019
- Effects of COVID-19 on the Nervous System Cell, 2020
- Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart Hypertension (Dallas, Tex. : 1979), 2023
- Effects of SGLT2 inhibitors on cardiac structure and function Heart failure reviews, 2023
- SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects International journal of environmental research and public health, 2019
- Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk Deutsche medizinische Wochenschrift (1946), 2016
- The cardiovascular phenotype: impact on choice of glucose- lowering therapy JPMA. The Journal of the Pakistan Medical Association, 2016
- Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications Current medicinal chemistry, 2018
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses Postgraduate medicine, 2019
- Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus Drugs of today (Barcelona, Spain : 1998), 2015
- SGLT inhibitors in management of diabetes The lancet. Diabetes & endocrinology, 2013
- Bolstering your armamentarium with SGLT2 inhibitors The Nurse practitioner, 2017
- Management of diabetes mellitus in patients undergoing liver transplantation Pharmacological research, 2019
- Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors Hypertension (Dallas, Tex. : 1979), 2020
- The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension Progress in cardiovascular diseases, 2020
- A year in heart failure: an update of recent findings ESC heart failure, 2021
- Empagliflozin/Linagliptin: A Review in Type 2 Diabetes Drugs, 2015
- Exploring the Therapeutic Potential of SGLT-2 Inhibitors in Managing Metabolic Syndrome: A Narrative Review Current drug research reviews, 2026
- Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians Postgraduate medicine, 2016
- SGLT2 inhibitors: their potential reduction in blood pressure Journal of the American Society of Hypertension : JASH, 2015
- Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved Hypertension (Dallas, Tex. : 1979), 2021
- Empagliflozin in the treatment of heart failure Future cardiology, 2024
- The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations Postgraduate medicine, 2017
- Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials Cardiology in review, 2020
- News in diabetology 2016 Revue medicale suisse, 2017
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment Expert opinion on drug safety, 2015
- Cardiovascular safety of therapies for type 2 diabetes Expert opinion on drug safety, 2017
- Advancing pharmacotherapy for diabetic foot ulcers Expert opinion on pharmacotherapy, 2019
- Novel Therapeutic Approaches in Diabetes Endocrine development, 2016
- The EMPA-REG outcome study: critical appraisal and potential clinical implications Cardiovascular diabetology, 2016
- Pharmacological aspects of the safety of gliflozins Pharmacological research, 2017
- Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives Basic & clinical pharmacology & toxicology, 2022
- Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology Journal of cardiology, 2017
- Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes Current diabetes reviews, 2020
- Canagliflozin and Amputation Risk: Evidence So Far The international journal of lower extremity wounds, 2020
- Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action Pharmacological research, 2025
- ▼ Empagliflozin, diabetes and outcomes Drug and therapeutics bulletin, 2016
- Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure Medicinal research reviews, 2014
- SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes European journal of pharmacology, 2019
- Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm Diabetes care, 2016
- Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials Diabetes, obesity & metabolism, 2019
- SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses Critical care nursing quarterly, 2022
- Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors International journal of molecular sciences, 2022
- The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia Current medicinal chemistry, 2020
- Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review Cardiovascular diabetology, 2023
- Risks Associated with SGLT2 Inhibitors: An Overview Current drug safety, 2018
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications Circulation, 2016
- Cardiovascular Outcomes of New Medications for Type 2 Diabetes Diabetes technology & therapeutics, 2016
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors Kidney international, 2018
- Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management Endocrine reviews, 2023
- Effect of Newly Approved Medications Sacubitril/Valsartan, Empagliflozin and Dapagliflozin on the Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction European Heart Journal, Supplement, 2023
- Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2024
- Patient not adequately controlled with insulin therapy and hospitalized for congestive heart failure ABOUTOPEN, 2018
- Mitochondrial Diabetes Treated With a Sodium-Glucose Co-Transporter 2 Inhibitor Journal of Endocrinology and Metabolism, 2019
- Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors University of Ottawa Journal of Medicine, 2019
- ODP130 Zoledronate-Induced Acute Tubular Necrosis With Baseline Normal Renal Function: A Rare Phenomenon Journal of the Endocrine Society, 2022
- Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy Endocrinology, Diabetes & Metabolism Case Reports, 2018
- SGLT2 Inhibitors and Perioperative Euglycemic Diabetic Ketoacidosis Anaesthesia & Critical Care Medicine Journal, 2023
- Peri‐procedural ketoacidosis risk with sodium‐glucose cotransporter 2 inhibitor use in people without diabetes Anaesthesia, 2023
- Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure Cardiovascular endocrinology & metabolism, 2023
- Fournier’s Gangrene and Sodium-Glucose Co-Transporter-2 Inhibitors: A Critical Combination in the Critical Care Unit Journal of Critical and Intensive Care, 2024
- Use of SGLT2 inhibition in the management of hyponatremia in a patient with metastatic cancer Journal of Onco-Nephrology, 2025
- A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed Case Reports in Endocrinology, 2020
- P0580ACUTE interstitial nephritis related to empagliflozin Nephrology, Dialysis and Transplantation, 2020
- Euglycemic ketoacidosis complicating empagliflozin therapy in a Bangladeshi type 2 diabetic lady BIRDEM Medical Journal, 2021
